TapImmune Announces the Appointment of Mark Reddish to the Board of Directors

Published on Monday, 30 April 2012 09:38 Written by TradersHuddle Staff

SEATTLE, April 30, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of Development at TapImmune and is responsible for developing the Company's product pipeline. He was formerly Vice President of Research & Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline. At Biomira Inc, Edmonton, Alberta (now renamed Oncothyreon, Seattle) he was responsible for preclinical development of their cancer vaccine program where he led the early research and clinical development of both Theratope and Stimuvax. Stimuvax is currently in late Stage 3 Clinical Trials partnered with Merk KGa/ Serono. Mark's corporate experience also extends to Baxter Healthcare and Bayer AG. He has a degree in Biology from Bates College and did graduate studies in Microbiology/Immunology at University of Massachusetts.

Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome the appointment of Mark to the Board. Mark is a leader in the development of Immunotherapies for cancer and infectious disease and brings to the Board a unique perspective and breadth of experience in this emerging field. More importantly he understands the challenges and strategies for innovative product design and development required for creation of a leading Immunotherapy organization."

Mark Reddish added, "I want to thank Glynn for the opportunity to work with him and the rest of our Board and Advisors to fully develop TapImmune's potential. Our core technology platform provides enormous opportunities for the development of new intellectual property and important products together with the establishment of multiple business partnerships."

About Tapimmune Inc.

Taplmmune Inc. is a vaccine technologies company specializing in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidates include vaccines designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently preparing for the commencement of a Phase 1 immunotherapy clinical trial targeting Her2Neu in breast cancer using a patented technology developed at the Mayo clinic. TapImmune has the exclusive Option to license this technology. The Company is also developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response. Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses.

The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACT: Glynn Wilson, Ph.D.
         Chairman & CEO
         (866)-359-7541